Malignancy risk stratification in thyroid nodules with benign results on cytology: Combination of thyroid imaging reporting and data system and bethesda system

Hee Jung Moon, Eunkyung Kim, jinyoung kwak

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: The indications of repeat fine-needle aspiration (FNA) for thyroid nodules with benign results of the Bethesda system were investigated. Methods: A total of 1,398 nodules were classified according to the Thyroid Imaging Reporting and Data System (TIRADS). TIRADS category 3 included nodules without solidity, hypoechogenicity or marked hypoechogenicity, microlobulated or irregular margins, microcalcifications, and taller-than-wide shape on ultrasonography (US). Categories 4a, 4b, 4c, and 5 included nodules with one, two, three or four, or five suspicious US features, respectively. The malignancy risks, and odds ratio (OR) with 95 % confidence interval (CI) were calculated. Analyses were performed for all nodules, nodules >10 mm, and nodules &10 mm. Results: Of 1.398 nodules, 43 (3.1 %) were malignanct. The malignancy risks of benign nodules with categories 3, 4a, and 4b were 0.7, 1.2, and 0.7 %, respectively, whereas those for nodules with categories 4c and 5 were 9.8 and 22.2 %, respectively. The ORs of nodules with categories 4c and 5 were 19.4 (95 % CI 5.0-76.2) and 50.6 (95 % CI 10.4-245.0), respectively. In nodules >10 mm, the malignancy risks of categories 4c and 5 were 2.7 and 20 %, respectively, and the ORs were 10.7 (95 % CI 1.2-93.7) and 236.1 (95 % CI 12.6-4426.4), respectively. In nodules 10 mm, the malignancy risks of categories 4c and 5 were 12.6 and 22.6 %, respectively, and the ORs were 10.1 (95 % CI 1.3-78.0) and 18.9 (95 % CI 2.1-168.9), respectively. Conclusions: Repeat US-guided FNA should be considered in benign thyroid nodules with three or more suspicious US features regardless of size.

Original languageEnglish
Pages (from-to)1898-1903
Number of pages6
JournalAnnals of Surgical Oncology
Volume21
Issue number6
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Thyroid Nodule
Information Systems
Cell Biology
Thyroid Gland
Confidence Intervals
Ultrasonography
Neoplasms
Fine Needle Biopsy
Odds Ratio
Calcinosis

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

@article{df808c609bfe46fdb193f76f313abffd,
title = "Malignancy risk stratification in thyroid nodules with benign results on cytology: Combination of thyroid imaging reporting and data system and bethesda system",
abstract = "Background: The indications of repeat fine-needle aspiration (FNA) for thyroid nodules with benign results of the Bethesda system were investigated. Methods: A total of 1,398 nodules were classified according to the Thyroid Imaging Reporting and Data System (TIRADS). TIRADS category 3 included nodules without solidity, hypoechogenicity or marked hypoechogenicity, microlobulated or irregular margins, microcalcifications, and taller-than-wide shape on ultrasonography (US). Categories 4a, 4b, 4c, and 5 included nodules with one, two, three or four, or five suspicious US features, respectively. The malignancy risks, and odds ratio (OR) with 95 {\%} confidence interval (CI) were calculated. Analyses were performed for all nodules, nodules >10 mm, and nodules &10 mm. Results: Of 1.398 nodules, 43 (3.1 {\%}) were malignanct. The malignancy risks of benign nodules with categories 3, 4a, and 4b were 0.7, 1.2, and 0.7 {\%}, respectively, whereas those for nodules with categories 4c and 5 were 9.8 and 22.2 {\%}, respectively. The ORs of nodules with categories 4c and 5 were 19.4 (95 {\%} CI 5.0-76.2) and 50.6 (95 {\%} CI 10.4-245.0), respectively. In nodules >10 mm, the malignancy risks of categories 4c and 5 were 2.7 and 20 {\%}, respectively, and the ORs were 10.7 (95 {\%} CI 1.2-93.7) and 236.1 (95 {\%} CI 12.6-4426.4), respectively. In nodules 10 mm, the malignancy risks of categories 4c and 5 were 12.6 and 22.6 {\%}, respectively, and the ORs were 10.1 (95 {\%} CI 1.3-78.0) and 18.9 (95 {\%} CI 2.1-168.9), respectively. Conclusions: Repeat US-guided FNA should be considered in benign thyroid nodules with three or more suspicious US features regardless of size.",
author = "Moon, {Hee Jung} and Eunkyung Kim and jinyoung kwak",
year = "2014",
month = "1",
day = "1",
doi = "10.1245/s10434-014-3556-2",
language = "English",
volume = "21",
pages = "1898--1903",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Malignancy risk stratification in thyroid nodules with benign results on cytology

T2 - Combination of thyroid imaging reporting and data system and bethesda system

AU - Moon, Hee Jung

AU - Kim, Eunkyung

AU - kwak, jinyoung

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: The indications of repeat fine-needle aspiration (FNA) for thyroid nodules with benign results of the Bethesda system were investigated. Methods: A total of 1,398 nodules were classified according to the Thyroid Imaging Reporting and Data System (TIRADS). TIRADS category 3 included nodules without solidity, hypoechogenicity or marked hypoechogenicity, microlobulated or irregular margins, microcalcifications, and taller-than-wide shape on ultrasonography (US). Categories 4a, 4b, 4c, and 5 included nodules with one, two, three or four, or five suspicious US features, respectively. The malignancy risks, and odds ratio (OR) with 95 % confidence interval (CI) were calculated. Analyses were performed for all nodules, nodules >10 mm, and nodules &10 mm. Results: Of 1.398 nodules, 43 (3.1 %) were malignanct. The malignancy risks of benign nodules with categories 3, 4a, and 4b were 0.7, 1.2, and 0.7 %, respectively, whereas those for nodules with categories 4c and 5 were 9.8 and 22.2 %, respectively. The ORs of nodules with categories 4c and 5 were 19.4 (95 % CI 5.0-76.2) and 50.6 (95 % CI 10.4-245.0), respectively. In nodules >10 mm, the malignancy risks of categories 4c and 5 were 2.7 and 20 %, respectively, and the ORs were 10.7 (95 % CI 1.2-93.7) and 236.1 (95 % CI 12.6-4426.4), respectively. In nodules 10 mm, the malignancy risks of categories 4c and 5 were 12.6 and 22.6 %, respectively, and the ORs were 10.1 (95 % CI 1.3-78.0) and 18.9 (95 % CI 2.1-168.9), respectively. Conclusions: Repeat US-guided FNA should be considered in benign thyroid nodules with three or more suspicious US features regardless of size.

AB - Background: The indications of repeat fine-needle aspiration (FNA) for thyroid nodules with benign results of the Bethesda system were investigated. Methods: A total of 1,398 nodules were classified according to the Thyroid Imaging Reporting and Data System (TIRADS). TIRADS category 3 included nodules without solidity, hypoechogenicity or marked hypoechogenicity, microlobulated or irregular margins, microcalcifications, and taller-than-wide shape on ultrasonography (US). Categories 4a, 4b, 4c, and 5 included nodules with one, two, three or four, or five suspicious US features, respectively. The malignancy risks, and odds ratio (OR) with 95 % confidence interval (CI) were calculated. Analyses were performed for all nodules, nodules >10 mm, and nodules &10 mm. Results: Of 1.398 nodules, 43 (3.1 %) were malignanct. The malignancy risks of benign nodules with categories 3, 4a, and 4b were 0.7, 1.2, and 0.7 %, respectively, whereas those for nodules with categories 4c and 5 were 9.8 and 22.2 %, respectively. The ORs of nodules with categories 4c and 5 were 19.4 (95 % CI 5.0-76.2) and 50.6 (95 % CI 10.4-245.0), respectively. In nodules >10 mm, the malignancy risks of categories 4c and 5 were 2.7 and 20 %, respectively, and the ORs were 10.7 (95 % CI 1.2-93.7) and 236.1 (95 % CI 12.6-4426.4), respectively. In nodules 10 mm, the malignancy risks of categories 4c and 5 were 12.6 and 22.6 %, respectively, and the ORs were 10.1 (95 % CI 1.3-78.0) and 18.9 (95 % CI 2.1-168.9), respectively. Conclusions: Repeat US-guided FNA should be considered in benign thyroid nodules with three or more suspicious US features regardless of size.

UR - http://www.scopus.com/inward/record.url?scp=84902196187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902196187&partnerID=8YFLogxK

U2 - 10.1245/s10434-014-3556-2

DO - 10.1245/s10434-014-3556-2

M3 - Article

C2 - 24558069

AN - SCOPUS:84902196187

VL - 21

SP - 1898

EP - 1903

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 6

ER -